Revised SPC: Nimbex (cisatracurium) 2mg/ml and Nimbex Forte 5mg/ml Injection

SPC now advises as a precaution that breast-feeding (BF) should be discontinued during treatment and it is recommended to abstain from next BF for five elimination half- lives of cisatracurium, i.e. for about 3 hours after the last dose or the end of infusion of cisatracurium.

SPS commentary:

SPC also updated to warn that very rarely, severe anaphylactic reactions have been reported in patients receiving cisatracurium in conjunction with one or more anaesthetic agents.

electronic Medicines compendium